RXRX is scaling its AI-driven drug discovery technology through billion-dollar pharma deals and strategic tech alliances.

In spite of this underperformance, the clinical-stage TechBio firm continues to attract interest for its innovative approach ...

Bullish option flow detected in Recursion Pharmaceuticals (RXRX) with 7,175 calls trading, 1.0x expected, and implied vol increasing almost 2 ...

Shares in biotech company Recursion Pharmaceuticals ( RXRX 12.07%) surged by more than 12% by 11 a.m. ET today. The move is ...

Investing.com - 摩根士丹利已恢复对Recursion Pharmaceuticals (NASDAQ: RXRX )的覆盖，给予"与大盘持平"评级，目标价为$5.00。根据 InvestingPro 数据，该股票目前交易价格接近其公允价值，分析师目标价范围为$4至$10。该公司保持"良好"的整体财务健康评分，尽管目前尚未盈利。

康涅狄格州纽黑文 - 目前股价接近0.34美元的临床阶段生物技术公司Rallybio Corporation (NASDAQ: RLYB )已同意将其在REV102（一种用于低磷酸酶症 (HPP)的临床前ENPP1抑制剂）中的权益出售给合资伙伴Recursion Pharmaceuticals，交易金额最高达2500万美元。根据 InvestingPro ...

Rallybio (NASDAQ:RLYB) shares climbed ~114% in the premarket on Tuesday after the company announced an agreement to sell its ...

Neurofibromatosis Type 2 Market Insight, Epidemiology and Market Forecast - 2034The Neurofibromatosis Type 2 treatment market is experiencin ...

Rallybio (RLYB) announced that it has entered into a definitive agreement to sell its interest in REV102, an ENPP1 inhibitor ...

Analysts have recently evaluated Recursion Pharmaceuticals and provided 12-month price targets. The average target is $7.4, accompanied by a high estimate of $11.00 and a low estimate of $5.00.

Rallybio sells its stake in preclinical HPP drug REV102 to Recursion in a deal worth up to $25 million, including equity and ...

Detailed price information for Recursion Pharmaceuticals Inc Cl A (RXRX-Q) from The Globe and Mail including charting and trades.